Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'

Bicara To Raise Funds In The Coming Fiscal Year

Biocon awaits site inspection after pandemic-amplified delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes they can still make good and garner market share. All eyes are also on traction for their insulin glargine via increased share of formulary contracts.

Pandemic induced misses dull momentum for Biocon • Source: Alamy

COVID-19 induced delays in regulatory inspections set back Biocon, Ltd.’s plans for biosimilar bevacizumab in the US, but the Indian firm underscored that the product partnered with Viatris Inc. can still quickly garner “good market share” in view of their “extremely competitive” position.

At the firm’s Q4 FY2021 earnings call, Biocon chairperson Kiran Mazumdar-Shaw said that 2020 was a “very difficult” year for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip